Nonviral gene delivery to T cells with Lipofectamine LTX
Authors:
- 22 January 2021
- journal article
- research article
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 118 (4) , 1674-1687
Abstract
Retroviral gene delivery is widely used in T cell therapies for hematological cancers. However, viral vectors are expensive to manufacture, integrate genes in semirandom patterns, and their transduction efficiency varies between patients. In this study, several nonviral gene delivery vehicles, promoters, and additional variables were compared to optimize nonviral transgene delivery and expression in both Jurkat and primary T cells. Transfection of Jurkat cells was maximized to a high efficiency (63.0% ± 10.9% EGFP+ cells) by transfecting cells with Lipofectamine LTX in X‐VIVO 15 media. However, the same method yielded a much lower transfection efficiency in primary T cells (8.1% ± 0.8% EGFP+). Subsequent confocal microscopy revealed that a majority of the lipoplexes did not enter the primary T cells, which might be due to relatively low expression levels of heparan sulfate proteoglycans detected via messenger RNA‐sequencing. Pyrin and HIN (PYHIN) DNA sensors (e.g., AIM2 and IFI16) that can induce apoptosis or repress transcription after binding cytoplasmic DNA were also detected at high levels in primary T cells. Therefore, transfection of primary T cells appears to be limited at the level of cellular uptake or DNA sensing in the cytoplasm. Both of these factors should be considered in the development of future viral and nonviral T cell gene delivery methods.Keywords
All Related Versions
Funding Information
- National Science Foundation (1645225, 1651837)
This publication has 70 references indexed in Scilit:
- An Efficient Low Cost Method for Gene Transfer to T LymphocytesPLOS ONE, 2013
- Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene TherapyHuman Gene Therapy, 2012
- Transfecting the hard-to-transfect lymphoma/leukemia cells using a simple cationic polymer nanocomplexJournal of Controlled Release, 2012
- Transfection optimization for primary human CD8+ cellsJournal of Immunological Methods, 2011
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaNew England Journal of Medicine, 2011
- The Impact of Ex Vivo Clinical Grade Activation Protocols on Human T-cell Phenotype and Function for the Generation of Genetically Modified Cells for Adoptive Cell Transfer TherapyJournal of Immunotherapy, 2010
- Systematic Comparison of Constitutive Promoters and the Doxycycline-Inducible PromoterPLOS ONE, 2010
- Optimization of the PiggyBac Transposon System for the Sustained Genetic Modification of Human T LymphocytesJournal of Immunotherapy, 2009
- Selective Modification of Antigen-Specific T Cells by RNA ElectroporationHuman Gene Therapy, 2008
- Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site PreferencesPLOS Biology, 2004